Literature DB >> 22191734

Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease.

Rachana Sainger1, Juan B Grau, Paolo Poggio, Emanuela Branchetti, Joseph E Bavaria, Joseph H Gorman, Robert C Gorman, Giovanni Ferrari.   

Abstract

CONTEXT: Calcific Aortic Valve Disease (CAVD) is an active pathological process leading to biomineralization of the aortic cusps. We characterized circulating and tissue Osteopontin (OPN) as a biomarker for CAVD.
OBJECTIVES: Here we investigate the post-translational modifications of circulating OPN and correlate the phosphorylation status with the ability to prevent calcification.
METHODS: Circulating OPN levels were estimated in CAVD patients (n = 51) and controls (n = 56). In a subgroup of 27 subjects, OPN was purified and the phosphorylation status analyzed.
RESULTS: Plasma OPN levels were significantly elevated in CAVD patients as compared to the controls and correlates with the aortic valve calcium score. Our study demonstrates that phospho-threonine levels of OPN purified from controls were higher when compared to CAVD subjects, whereas phospho-serine and phospho-tyrosine levels were comparable between the two groups.
CONCLUSION: The dephosphorylation of circulating OPN correlates with severe valvular calcification in patients with CAVD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22191734      PMCID: PMC3291739          DOI: 10.3109/1354750X.2011.642407

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  34 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  Plasma homocysteine and calcific aortic valve disease.

Authors:  G M Novaro; H D Aronow; E Mayer-Sabik; B P Griffin
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

3.  Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis.

Authors:  Matthew R Reynolds; Elizabeth A Magnuson; Yang Lei; Martin B Leon; Craig R Smith; Lars G Svensson; John G Webb; Vasilis C Babaliaros; Bruce S Bowers; William F Fearon; Howard C Herrmann; Samir Kapadia; Susheel K Kodali; Raj R Makkar; Augusto D Pichard; David J Cohen
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

4.  Progression of valvar aortic stenosis: a long-term retrospective study.

Authors:  S W Davies; A H Gershlick; R Balcon
Journal:  Eur Heart J       Date:  1991-01       Impact factor: 29.983

5.  Predictors of outcome in severe, asymptomatic aortic stenosis.

Authors:  R Rosenhek; T Binder; G Porenta; I Lang; G Christ; M Schemper; G Maurer; H Baumgartner
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

6.  Human aortic valve calcification is associated with an osteoblast phenotype.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; David Rickard; Stuart R Stock; Janis Donovan; Margaret Springett; Thomas Orszulak; David A Fullerton; A J Tajik; Robert O Bonow; Thomas Spelsberg
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

7.  Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis.

Authors:  Jutta Bergler-Klein; Ursula Klaar; Maria Heger; Raphael Rosenhek; Gerald Mundigler; Harald Gabriel; Thomas Binder; Richard Pacher; Gerald Maurer; Helmut Baumgartner
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

8.  Balloon aortic valvoplasty in paediatric patients: progressive aortic regurgitation is common.

Authors:  C Balmer; M Beghetti; M Fasnacht; B Friedli; U Arbenz
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

Review 9.  Calcific aortic stenosis: same old story?

Authors:  S Joanna Cowell; David E Newby; Nicholas A Boon; Andrew T Elder
Journal:  Age Ageing       Date:  2004-08-12       Impact factor: 10.668

Review 10.  Regulation of cardiovascular calcification.

Authors:  Mei Y Speer; Cecilia M Giachelli
Journal:  Cardiovasc Pathol       Date:  2004 Mar-Apr       Impact factor: 2.185

View more
  11 in total

1.  Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Emanuela Branchetti; Paolo Poggio; Eric Lai; Erblina Koka; William J Vernick; Robert C Gorman; Joseph E Bavaria; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2013-03

2.  Osteopontin in Vascular Disease.

Authors:  Zoe Shin Yee Lok; Alicia N Lyle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

3.  Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis.

Authors:  Emanuela Branchetti; Rachana Sainger; Paolo Poggio; Juan B Grau; Jeffrey Patterson-Fortin; Joseph E Bavaria; Michael Chorny; Eric Lai; Robert C Gorman; Robert J Levy; Giovanni Ferrari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

4.  Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease.

Authors:  Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari
Journal:  Physiol Genomics       Date:  2020-02-24       Impact factor: 3.107

5.  Degeneration of Aortic Valves in a Bioreactor System with Pulsatile Flow.

Authors:  Naima Niazy; Mareike Barth; Jessica I Selig; Sabine Feichtner; Babak Shakiba; Asya Candan; Alexander Albert; Karlheinz Preuß; Artur Lichtenberg; Payam Akhyari
Journal:  Biomedicines       Date:  2021-04-23

6.  Muscleblind-like 1 is required for normal heart valve development in vivo.

Authors:  Ryan J Coram; Samantha J Stillwagon; Anuradha Guggilam; Michael W Jenkins; Maurice S Swanson; Andrea N Ladd
Journal:  BMC Dev Biol       Date:  2015-10-15       Impact factor: 1.978

7.  Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio.

Authors:  Jani Luukkonen; Laia Mira Pascual; Christina Patlaka; Pernilla Lång; Sanna Turunen; Jussi Halleen; Tomi Nousiainen; Maarit Valkealahti; Juha Tuukkanen; Göran Andersson; Petri Lehenkari
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

Review 8.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.

Authors:  Florian Kahles; Hannes M Findeisen; Dennis Bruemmer
Journal:  Mol Metab       Date:  2014-03-22       Impact factor: 7.422

9.  Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors.

Authors:  Michael Sponder; Christian Reuter; Monika Fritzer-Szekeres; Brigitte Litschauer; Thomas Binder; Jeanette Strametz-Juranek
Journal:  BMC Cardiovasc Disord       Date:  2016-06-10       Impact factor: 2.298

Review 10.  Vascular Calcification-New Insights Into Its Mechanism.

Authors:  Sun Joo Lee; In-Kyu Lee; Jae-Han Jeon
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.